Replies to post #45598 on PharmaCyte Biotech Inc (PMCB)

[$Pistol Pete$]

$PMCB Mature markets will push major pharmaceutical companies to seek more deals. Hopefully $PMCB will be on the list as well.

The world's pharmaceutical giants struggle to generate additional revenue at the rate investors expect, and are projected to lose $17 billion from expired patents in 2016, according to PricewaterhouseCoopers. As a result, executives are eager to acquire fast-growing businesses to show growth. In 2015, pharmaceutical and biotech companies set a new record for the value of the deals they struck in a single year at $462.2 billion. The sheer volume of deals also grew by 21.5 percent, up to 768 deals, from 632 in 2014, according to EY.

http://www.ibtimes.com/top-pharma-biotech-trends-what-watch-out-2016-2235052?rel=rel1

[ace1234]

The thing is Frosr, it's too early to make that call yet, and big pharma is waiting until the results show it.

Big pharma is waiting on PMCB to do the work and heavy lifting. Otherwise, it's too big of a risk at this stage. After trials, though, I am sure you will see the big fish bite.